Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Table 3 Description and persistence of the treatment administered from the series studied (CI 95%)

Subjects	N = 191
Time since diagnosis, years
Mean (SD)	8.0 (3.7)
Median (P25 - P75)	9.0 (4.5-10.5)
Duration of the treatment (single therapy), months
Mean (SD)	15.7 (13.5)
Median (P25 - P75)	14.1 (2.0-23.3)
Duration of the treatment (double therapy), months
Mean (SD)	10.2 (7.1)
Median (P25 - P75)	9.0 (4.0-11.5)
Treatment persistence^a
Persistence on double therapy, 12 months	65.4%
CI 95%	58.8-72.2%

Values expressed as mean (SD: standard deviation) or percentage, P: percentiles
^a Persistence was defined as the time, measured in months, without the patient dropping out of the initial treatment or without switching to another medication at least 30 days after the initial prescription. A patient was classified as being persistent if they had no treatment discontinuation or switch to another medication during the 12-month follow-up period. CI: Confident Interval

ISSN: 1471-2490